Nuveen
AKBA icon

Nuveen’s Akebia Therapeutics AKBA Stock Holding History

Nuveen’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$680K Hold
596,599
– – ﹤0.01% 3129
2026
Q1 		$829K Buy
596,599
+3,608
+0.6% +$4.96K ﹤0.01% 2662
2025
Q4 		$955K Sell
592,991
-1,708,386
-74% -$3.58M ﹤0.01% 2638
2025
Q3 		$6.28M Sell
2,301,377
-407,299
-15% -$1.35M ﹤0.01% 1800
2025
Q2 		$9.86M Buy
2,708,676
+2,358,263
+673% +$6.48M ﹤0.01% 1514
2025
Q1 		$20.5M Sell
350,413
-30,122
-8% -$61.5K 0.01% 1122
2024
Q4 		$723K Hold
380,535
– – ﹤0.01% 2840
2024
Q3 		$502K Hold
380,535
– – ﹤0.01% 3018
2024
Q2 		$388K Buy
+380,535
New +$470K ﹤0.01% 3076
2022
Q1 		– Sell
-580,106
Closed -$1.33M – 3390
2021
Q4 		$1.33M Buy
580,106
+7,107
+1% +$19.4K ﹤0.01% 2744
2021
Q3 		$1.66M Sell
572,999
-7,011
-1% -$20K ﹤0.01% 2759
2021
Q2 		$2.2M Buy
580,010
+63,267
+12% +$213K ﹤0.01% 2665
2021
Q1 		$1.75M Sell
516,743
-300
-0.1% -$1.08K ﹤0.01% 2680
2020
Q4 		$5.17M Sell
517,043
-1,154,823
-69% -$3.37M ﹤0.01% 2054
2020
Q3 		$16.7M Buy
1,671,866
+98,926
+6% +$868K 0.01% 1180
2020
Q2 		$21.4M Buy
1,572,940
+87,084
+6% +$901K 0.01% 1000
2020
Q1 		$11.3M Sell
1,485,856
-241,427
-14% -$1.88M 0.01% 1220
2019
Q4 		$10.9M Buy
1,727,283
+13,777
+0.8% +$65.5K ﹤0.01% 1543
2019
Q3 		$6.72M Buy
1,713,506
+84,478
+5% +$362K ﹤0.01% 1794
2019
Q2 		$7.88M Buy
+1,629,028
New +$9.27M ﹤0.01% 1748

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nuveen's AKBA Position: Q2 2026 in Review

Nuveen held its Akebia Therapeutics (AKBA) position steady in Q2 2026 at 596,599 shares worth $680K. The position accounts for ﹤0.01% of the portfolio, ranked #3129.

Nuveen first reported a position in AKBA in Q2 2019 and has held it in 20 quarters since. The position peaked at $21.4M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Nuveen held 596,599 shares of Akebia Therapeutics worth $680K as of Q2 2026.
  • Nuveen left its Akebia Therapeutics share count unchanged in Q2 2026.
  • Akebia Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3129 holding.
  • Nuveen first reported a position in Akebia Therapeutics in Q2 2019 and has held it in 20 quarters since.
  • Nuveen's Akebia Therapeutics position peaked at $21.4M in Q2 2020.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.